SCHEDULE: Vanguard Reports 4.99% Stake in Xencor
Ownership Filing
Vanguard Capital Management has disclosed beneficial ownership of 4.99% of Xencor Inc.'s common stock as of September 30, 2026.
Summary
- Vanguard Capital Management, along with its affiliates, now beneficially owns 3,710,894 shares of Xencor Inc. common stock.
- This ownership stake represents 4.99% of the class of securities.
- The filing is an amendment to a previous Schedule 13G, indicating a change in reporting status.
- The reporting date for this ownership is September 30, 2026.
- Vanguard Capital Management exercises sole dispositive power over these shares.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral filing, primarily reflecting a routine ownership update by a large institutional investor without significant new strategic or financial information.
Positives
- Vanguard's continued investment, even at a threshold below 5%, can be seen as a sign of confidence in Xencor's long-term prospects.
- The filing clarifies Vanguard's ownership structure, including various affiliates and managed accounts.
Negatives
- The filing does not provide any new financial performance data or strategic updates for Xencor.
- The ownership stake is just below the 5% threshold that triggers more detailed disclosure requirements, suggesting no immediate intent to influence control.
Risks
- As a Schedule 13G filing, it indicates passive investment, meaning Vanguard is not actively seeking to control Xencor. However, significant changes in ownership by large institutional investors can sometimes precede strategic shifts or market reactions.
- The filing does not detail specific reasons for the ownership level, leaving room for speculation about Vanguard's evolving investment thesis.
Future Outlook
This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding Xencor's future performance.
Management Comments
- In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd.
- This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power.
- This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.
- By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
Industry Context
StockSavvy.ai notes that Xencor operates in the competitive biotechnology sector. Large institutional investors like Vanguard often hold stakes across many companies in this sector, and their ownership levels can fluctuate based on portfolio management strategies and market opportunities. This filing indicates Vanguard's passive investment in Xencor.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which may influence market perception but does not immediately alter corporate control or strategy.
- Management: The filing confirms Vanguard's passive investment, indicating no immediate pressure for control changes from this investor.
- Potential Investors: The disclosure provides data on institutional ownership, which is a factor in investment analysis.
Next Steps
- Vanguard will continue to monitor its investment in Xencor and may adjust its holdings based on market conditions and company performance.
- Xencor will continue its operations and strategic initiatives, with Vanguard's passive stake noted.
Key Dates
| Date | Description |
|---|---|
| 1998-01-12 | SEC Release No. 34-39538 referenced for reporting securities ownership. |
| 2026-09-30 | Date of Event Which Requires Filing of this Statement (Ownership as of this date). |
| 2026-10-30 | Date of Certification and Signature by Vanguard Capital Management. |
Keywords
Xencor, Vanguard, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.